Uncategorized
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%
Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial
Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck
HHS Overhaul: RFK Jr. Cuts 20,000 Jobs in Major Restructuring
Robert F. Kennedy Jr., Department of Health and Human Services (HHS), job cuts, restructuring, Administration for a Healthy America (AHA), chronic disease epidemic, efficiency, cost-saving
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
Equillium’s pivotal GvHD study of anti-CD6 antibody comes up short
United States Food and Drug Administration, itolizumab, In complete remission, day, Equillium
Galatea Bio’s $25M Funding Boost for Global Biobank and AI-Driven Genomic Research
Galatea Bio, global biobank, AI-enabled genomic analysis, precision medicine, non-European ancestry, genetic diversity
Drugmakers fear Trump tariffs will drive up manufacturing costs, hurt medicine access: BIO survey
Manufacture, EU, Surveys, Financial cost, Fear (Mental Process), Bio
Nkarta lays off 3rd of staff, including CFO, to fund autoimmune CAR NK program
Nkarta, restructuring, Allogeneic CD19-OX40-CD3zeta-CAR-mbIL-15-expressing Natural Killer Cells NKX019, Cell Therapy